Abstract
Recombinant human deoxyribonuclease I (rhDNase) is a new therapeutic agent developed to improve clearance of purulent sputum from the human airways. It is delivered by inhalation. Four jet nebulizers, T Up-Draft II (Hudson), Customized Respirgard II (Marquest), Acorn II (Marquest), and Airlife Misty (Baxter), were evaluated in vitro for their ability to deliver aerosols of rhDNase. The aerosols were generated from 2.5-mL aqueous solutions of rhDNase, at concentrations of either 1 or 4 mg/mL. In all experiments, the Pulmo-Aide Compressor (De Vilbiss) was used to supply the air to the nebulizers. Between 20 and 28% of the rhDNase dose initially placed in the nebulizers was delivered to the mouthpiece in the respirable range (1-6 µm). Evaluation of the rhDNase following nebulization in all four devices indicated that there was no loss in enzymatic activity and no increase in aggregation. Circular dichroism spectrophotometry indicated there was no change in either the secondary or the tertiary structure in rhDNase following nebulization. These results show that all four nebulizers are essentially equivalent in their ability to deliver respirable doses of rhDNase in an intact, fully active form. Changing the concentration of the solution in the nebulizer from 4 to 1 mg/mL rhDNase leads to a proportional reduction in the respirable dose delivered to the mouthpiece.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
S. Shak, D. J. Capon, R. Helmiss, S. A. Marsters and C. L. Baker. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc. Natl. Acad. Sci. 87:9188–9192 (1990).
R. C. Hubbard, N. G. McElvaney, P. Birrer, S. Shak, W. W. Robinson, C. Jolley, M. Wu, M. S. Chernick, and R. G. Crystal. A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis. N. Engl. J. Med. 326:812–815.
M. L. Aitken, W. Burke, G. McDonald, S. Shak, A. B. Montgomery, and A. Smith. Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis. JAMA 267:1947–1951 (1992).
P. R. Byron. Aerosol formulation, generation, and delivery using nonmetered systems. In P. R. Byron (ed.), Respiratory Drug Delivery, CRC Press, Boca Raton, FL, 1990, Chap. 6.
I. Gonda. A semi-empirical model of aerosol deposition in the human respiratory tract for mouth inhalation. J. Pharm. Pharmacol. 33:692–696 (1981).
I. Gonda. Study of the effects of polydispersity on regional deposition in the respiratory tract. J. Pharm. Pharmacol. 33(Suppl):52P (1981).
G. Rudolph, J. Gebhart, J. Heyder, G. Scheuch, and W. Stahlhofen. Mass deposition from inspired polydisperse aerosols. Ann. Occup. Hyg. 32(Suppl 1):919–938 (1988).
T. A. Horbett. Adsorption of proteins and peptides at interfaces. In T. J. Ahern and M. C. Manning (eds.), Stability of Protein Pharmaceuticals, Part A: Chemical and Physical Pathways of Degradation, Plenum Press, New York, 1992, pp. 195–210.
W. C. Hinds. Aerosol Technology: Properties, Behavior, and Measurement of Airborne Particles, John Wiley and Sons, 1982.
S. Bolton. Pharmaceutical Statistics, 2nd ed., Marcel Dekker, New York, 1990, Chap. 8.
A. F. Winder and W. L. G. Gent. Correction of light-scattering errors in spectrophotometric protein determinations. Biopolymers 10:1243–1251 (1971).
N. B. Kurnick. The determination of desoxyribonuclease activity by methyl green application to serum. Arch. Biochem. 29:41–53 (1950).
P. R. Phipps and I. Gonda. Droplets produced by medical nebulizers. Chest 97:1327–1332 (1990).
T. T. Mercer, M. I. Tillery, and H. Y. Chow. Operating characteristics of some compressed air nebulizers. Am. Ind. Hyg. Assoc. J. 29:66–78 (1968).
S. P. Newman, P. G. D. Pellow, M. M. Clay, and S. W. Clarke. Evaluation of jet nebulizers for use with gentamicin solution. Thorax 40:671–676 (1985).
S. S. Davis. Physico-chemical studies on aerosol solutions for drug delivery. I. Water-propylene glycol systems. Int. J. Pharm. 1:71–83 (1978).
J. Q. Oeswein, A. L. Daugherty, E. J. Cornavaca, J. A. Moore, H. M. Gustafson, B. M. Eckhardt, H. J. Fuchs, G. A. Keller, and J. S. Patton. Aerosolization of protein pharmaceuticals. In R. N. Dalby and R. Evans (eds.), Proceedings of the 2nd Respiratory Drug Delivery Symposium, Continuing Pharmaceutical Education, University of Kentucky, 1991, pp. 14–49.
H. E. Strickland, C. Billups, and E. Kay. Effects of hydrogen bonding and solvents upon the tryptophanyl 1La absorption band. Studies using 2,3-dimethylindole. Biochemistry 11:3657–3662 (1972).
R. W. Niven, J. P. Butler, and J. D. Brain. How air jet nebulizers may damage “sensitive” drug formulations. Abstracts, 11th Annual Meeting of the American Association for Aerosol Research, October 12–16, 1992, San Francisco, CA, Abstr. 6A.5, p. 160.
R. A. Lewis. Therapeutic aerosols. In G. Cumming and G. Bonsignore (eds.), Drugs and the Lung, Plenum Press, New York, 1984, pp. 63–83.
H. J. Fuchs. Aerosolized rhDNase: A clinical overview. The rhDNase Research Consortium. Pediatr. Pulmonol. Suppl. 8:149 (1992).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cipolla, D., Gonda, I. & Shire, S.J. Characterization of Aerosols of Human Recombinant Deoxyribonuclease I (rhDNase) Generated by Jet Nebulizers. Pharm Res 11, 491–498 (1994). https://doi.org/10.1023/A:1018998028490
Issue Date:
DOI: https://doi.org/10.1023/A:1018998028490